Abstract
The ainich of study was to investigate the efficacy and toxicity of sulphasalazine (SASP) in the treatment of children with chronic arthritis. The medical records of 36 children (25 boys, 11 girls) who received SASP for the treatment of chronic arthritis were reviewed. Twenty-one patients had juvenile spondyloarthropathies (JSA) (eight juvenile ankylosing spondylitis (JAS), 13 undifferentiated JSA (uJSA) and 15 had juvenile rheumatoid arthritis (JRA). The patients received SASP therapy for a mean of 2.5 years (range 3 weeks to 8.1 years). Clinical and laboratory data were reviewed retrospectively to determine the effects of treatment. A clinically significant response occurred in 23 (64%) children: remission in 14 (39%) (JRA 5, JSA 9) and improvement (25% reduction in joint count) in nine (25%) (JRA 4, JSA 5). There was no difference in response rate between JR and JSA patients (p=0.11), but the time to remission shorter in JSA patients (mean 5 months) JRA patients (mean 25 months) (p=0.024). Twelve of the 36 patients discontinued non-steroidal anti-inflammatory drugs, and six of eight patients discontinued prednisolone. A significant fall in erythrocyte sedimentation rate and rise in haemoglobin occurred in SASP-treated patients (p<0.005) comparing most recent results with pretreatment levels. Side-effects occurred in four of 36 patients (11%); only one patient who had persisting severe diarrhoea required discontinuation of SASP. It was concluded that SASP appears to be effective and safe in the treatment of JRA and JSA patients. As a second-line agent, SASP is the drug of first choice for patients with JSA; for JRA patients SASP may be a useful, possibly less toxic alternative to methotrexate.
Similar content being viewed by others
References
McConkey B, Amos RS, Butcher RA, et al. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;279:442–4.
Neumann VC, Grundulis KA, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. Br Med J 1983;287:1099–102.
Bax DE, Amos RS. Sulphasalazine: a safe effective agent for prolonged control of rheumatoid arthritis: a comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194–8.
Nissila M, Lehtinen K, Leirisalo-Repo M, Luukhainen R, Mutru O, Yli-Kertula U. Sulphasalazine in the treatment of ankylosing spondylitis. Arthritis Rheum 1988;31:1111–6.
Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of establishing ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729–33.
Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 1986;293:911–4.
Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 1983;287:1102–4.
Pinala RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427–34.
Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702–13.
Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalysis. Arthritis Rheum 1990;33:1449–61.
Nuver-Zwart IH, van Riel PLCM, van de Putte LBA, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989;48:389–95.
Wijnands MJH, van Hof MA, van Leeuwen MA, van Rijswijle MH, van de Putte LBA, van riel PLCM. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253–8.
Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501–9.
Ozdogan H, Turuns M, Deringol B, Yurdakul S, Yazici H. Sulphasalazine in the treatment of rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986;13:124–5.
Imundo LF, Jacobs JC. Treatment of juvenile arthritis (JA) with sulphasalazine. Arthritis Rheum 1993;36(suppl):s122.
Joos R, Veys EM, Mielants H, van Werveke S, Goemaere S. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991;18:880–4.
Ansell BM, Hall MA, Loftus JK, et al. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201–3.
Job-Deslandre C, Menkes CJ. Sulphasalazine in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 1991;34 (suppl):s153
Susche HJ. Treatment of juvenile spondyloarthritis and reactive arthritis with sulphasalazine. Monatsschr Kinderheilkd 1992;140:658–60.
Burgos-Vargas R, Pacheco-Tena C, Vazguez-Mellado J. Juvenileonset spondyloarthropathy. Rheum Dis Clin North Am 1997;23:569–99.
Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977;20(suppl):195–9.
Bennett BH, Birch TA. New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 1967;25:1041–7.
Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982;25:1041–7.
Cabral DA, Oen Kg, Petty RE. SEA syndrome revisited: a longerm follow-up of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992;19:1282–5.
Burgos-Vargas R, Clark P. Axial involvement of the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989;16:192–7.
Hussein A, Abdul-Khaliq H, von der Hardt H. Atypical spondyloarthritis in children: proposed diagnostic criteria. Eur J Pediatr 1989;148:513–7.
Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982;100:521–8.
Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983;24:213–7.
Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leukocyte motility by drugs used in ulcerative colitis. Gut 1981;22:642–7.
Carter SD, Bacon PA, Hall ND. Characterization of activated lymphocytes in the peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis 1981;40:293–8.
Madhok R, Wijelath E, Smith J, Watson J, Sturrock RD, Capell HA. Is the beneficial effect of sulphasalazine due to inhibition of synovial neovascularization? J Rheumatol 1991;18:199–202.
Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH. Inhibition of leukocyte adhesion molecule upregulation by tumor necrosis factor: a novel mechanism of action of sulphasalazine. Gut 1993;34:256–6.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Huang, JL., Chen, LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 17, 359–363 (1998). https://doi.org/10.1007/BF01450892
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01450892